<?xml version="1.0" encoding="utf-8"?>
<rdf:RDF 
					 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
					 xmlns="http://purl.org/rss/1.0/"
					 xmlns:dc="http://purl.org/dc/elements/1.1/"
					>
<channel rdf:about="http://www.thrombosisadviser.com"><title>Thrombosis Adviser News</title>
<link>http://www.thrombosisadviser.com</link>
<description><![CDATA[Latest Updates and News on ThrombosisAdviser.com]]></description>
<items>
<rdf:Seq>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=CLOTS+3%3A+Inflatable+Leg+Sleeves+Reduce+DVT+in+Stroke#news1272"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Beta-blockers+benefit+heart+surgery+cases#news1271"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Rivaroxaban+Gains+Approval+In+Europe+For+ACS+Indication#news1270"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Risk+Profiles+and+Antithrombotic+Treatment+of+Patients+Newly+Diagnosed+with+Atrial+Fibrillation+at+Risk+of+Stroke%3A+Perspectives+from+the+International%2C+Observational%2C+Prospective+GARFIELD+Registry#news1269"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Systematic+screening+for+atrial+fibrillation+%27better+than+routine+GP+practice%27#news1268"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Antiplatelet+Effects+of+Aspirin%3A+Which+NSAIDs+Interact%3F#news1267"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Repeat+ablation+wins+out+over+antiarrhythmic+agents+for+recurrent+paroxysmal+AF#news1266"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=%27Clean%27+Vessels+Seen+in+Some+Young+MI+Patients#news1265"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=7+simple+lifestyle+steps+may+lower+risk+of+blood+clot#news1264"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=ESC+guide+on+new+oral+anticoagulant+drugs#news1263"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=ACS+assessment+tools+released+by+ACP#news1262"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Anticoagulant+Boosts+Benefit+of+Antiplatelet+After+Stenting#news1261"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=LAFB+associated+with+long-term+cardiovascular+and+mortality+risk#news1260"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=ACP+unveils+tools+to+improve+health+outcomes+in+patients+following+ACS+event#news1259"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Steriod+use+doubles+risk+of+venous+thromboembolism#news1258"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=New+Drugs+Better+Value+Than+Warfarin#news1257"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Stent+type+may+influence+thrombosis+rates+in+patients+with+diabetes#news1256"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Women+experiencing+still+birth+are+more+likely+to+develop+blood+clots%2C+says+study#news1255"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=European+committee+adopts+positive+opinion+on+rivaroxaban+for+ACS#news1254"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Thrombosis+publications+recommended+by+the+Board+of+Advisers+has+been+updated+for+February+2013.#news1253"/>
<rdf:li resource="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Pregnancy-associated+plasma+protein+A+predicts+cardiovascular+events%3A+Study#news1252"/>
</rdf:Seq>
</items>
</channel>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=CLOTS+3%3A+Inflatable+Leg+Sleeves+Reduce+DVT+in+Stroke#news1272">
<title>CLOTS 3: Inflatable Leg Sleeves Reduce DVT in Stroke</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=CLOTS+3%3A+Inflatable+Leg+Sleeves+Reduce+DVT+in+Stroke#news1272</link>
<dc:date>2013-06-04</dc:date>
<description><![CDATA[Intermittent pneumatic compression with inflatable sleeves that fit over the legs reduced the occurrence of deep vein thrombosis (DVT) in immobile patients who had had a recent stroke in the CLOTS 3 study.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Beta-blockers+benefit+heart+surgery+cases#news1271">
<title>Beta-blockers benefit heart surgery cases</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Beta-blockers+benefit+heart+surgery+cases#news1271</link>
<dc:date>2013-06-04</dc:date>
<description><![CDATA[Using beta-blockers after heart surgery reduces the risk of dangerous abnormal heart rhythms, according to a analysis. One complication after heart surgery is atrial fibrillation (AF), where the two upper chambers of the heart quiver, rather than beating effectively.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Rivaroxaban+Gains+Approval+In+Europe+For+ACS+Indication#news1270">
<title>Rivaroxaban Gains Approval In Europe For ACS Indication</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Rivaroxaban+Gains+Approval+In+Europe+For+ACS+Indication#news1270</link>
<dc:date>2013-05-28</dc:date>
<description><![CDATA[Rivaroxaban […] has been approved in Europe for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction or stroke) following an acute coronary syndrome (ACS). The drug was approved at a dose of 2.5 mg twice-daily and should be used in combination with standard antiplatelet therapy. Rivaroxaban is now the only oral anticoagulant to receive an ACS indication.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Risk+Profiles+and+Antithrombotic+Treatment+of+Patients+Newly+Diagnosed+with+Atrial+Fibrillation+at+Risk+of+Stroke%3A+Perspectives+from+the+International%2C+Observational%2C+Prospective+GARFIELD+Registry#news1269">
<title>Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Risk+Profiles+and+Antithrombotic+Treatment+of+Patients+Newly+Diagnosed+with+Atrial+Fibrillation+at+Risk+of+Stroke%3A+Perspectives+from+the+International%2C+Observational%2C+Prospective+GARFIELD+Registry#news1269</link>
<dc:date>2013-05-28</dc:date>
<description><![CDATA[These contemporary observational worldwide data on non-valvular atrial fibrillation, collected at the end of the vitamin K antagonist-only era, indicate that these drugs are frequently not being used according to stroke risk scores and guidelines, with overuse in patients at low risk and underuse in those at high risk of stroke.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Systematic+screening+for+atrial+fibrillation+%27better+than+routine+GP+practice%27#news1268">
<title>Systematic screening for atrial fibrillation 'better than routine GP practice'</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Systematic+screening+for+atrial+fibrillation+%27better+than+routine+GP+practice%27#news1268</link>
<dc:date>2013-05-15</dc:date>
<description><![CDATA[Systematic screening in GP practices for atrial fibrillation could identify more people with the disease than routine practice, according to a gold-standard review.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Antiplatelet+Effects+of+Aspirin%3A+Which+NSAIDs+Interact%3F#news1267">
<title>Antiplatelet Effects of Aspirin: Which NSAIDs Interact?</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Antiplatelet+Effects+of+Aspirin%3A+Which+NSAIDs+Interact%3F#news1267</link>
<dc:date>2013-05-15</dc:date>
<description><![CDATA[Low-dose aspirin is widely used as prevention for myocardial infarction and other cardiovascular diseases, but there is evidence that concurrent use of NSAIDs may inhibit the antiplatelet effect of aspirin.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Repeat+ablation+wins+out+over+antiarrhythmic+agents+for+recurrent+paroxysmal+AF#news1266">
<title>Repeat ablation wins out over antiarrhythmic agents for recurrent paroxysmal AF</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Repeat+ablation+wins+out+over+antiarrhythmic+agents+for+recurrent+paroxysmal+AF#news1266</link>
<dc:date>2013-05-15</dc:date>
<description><![CDATA[Should recurrences after a failed ablation in patients with paroxysmal atrial fibrillation (AF) be treated with antiarrhythmic drugs (AAD) or with a repeat pulmonary vein isolation (PVI) procedure? More likely second time's the charm, suggests a randomized trial showing that repeat ablation is much more likely than AAD to get rid of a recurrence.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=%27Clean%27+Vessels+Seen+in+Some+Young+MI+Patients#news1265">
<title>'Clean' Vessels Seen in Some Young MI Patients</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=%27Clean%27+Vessels+Seen+in+Some+Young+MI+Patients#news1265</link>
<dc:date>2013-05-15</dc:date>
<description><![CDATA[Although young patients with acute coronary syndromes typically carry traditional cardiovascular risk factors, some of them show no evidence of underlying coronary artery disease, researchers found.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=7+simple+lifestyle+steps+may+lower+risk+of+blood+clot#news1264">
<title>7 simple lifestyle steps may lower risk of blood clot</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=7+simple+lifestyle+steps+may+lower+risk+of+blood+clot#news1264</link>
<dc:date>2013-05-08</dc:date>
<description><![CDATA[Adopting seven simple lifestyle steps could help reduce your risk of these potentially deadly blood clots, according to a new study.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=ESC+guide+on+new+oral+anticoagulant+drugs#news1263">
<title>ESC guide on new oral anticoagulant drugs</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=ESC+guide+on+new+oral+anticoagulant+drugs#news1263</link>
<dc:date>2013-05-08</dc:date>
<description><![CDATA[A practical guide on the use of the new oral anticoagulants (NOACs) has been produced by the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). A guide was needed to summarise existing information on different drugs, to answer clinical questions that fall outside what drug companies can legally answer, and to make distinctions between the different drugs.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=ACS+assessment+tools+released+by+ACP#news1262">
<title>ACS assessment tools released by ACP</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=ACS+assessment+tools+released+by+ACP#news1262</link>
<dc:date>2013-05-08</dc:date>
<description><![CDATA[In an effort to better the lives of patients in the first year after an initial acute coronary syndrome (ACS) event, the American College of Physicians (ACP) has released a pair of evidence-based interventions and two videos for clinicians and patients to heed.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Anticoagulant+Boosts+Benefit+of+Antiplatelet+After+Stenting#news1261">
<title>Anticoagulant Boosts Benefit of Antiplatelet After Stenting</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Anticoagulant+Boosts+Benefit+of+Antiplatelet+After+Stenting#news1261</link>
<dc:date>2013-05-08</dc:date>
<description><![CDATA[Add-on anticoagulant therapy after stent deployment for acute coronary syndromes (ACS) significantly reduced the risk of stent thrombosis and mortality in patients already receiving dual antiplatelet therapy, according to a new analysis of a large randomized trial.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=LAFB+associated+with+long-term+cardiovascular+and+mortality+risk#news1260">
<title>LAFB associated with long-term cardiovascular and mortality risk</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=LAFB+associated+with+long-term+cardiovascular+and+mortality+risk#news1260</link>
<dc:date>2013-04-18</dc:date>
<description><![CDATA[Left anterior fascicular block (LAFB), an electrocardiographic abnormality previously considered benign, is associated with a significantly increased long-term risk of atrial fibrillation (AF), congestive heart failure, and death, according to the results of a new analysis published April 16, 2013 in the Journal of the American Medical Association.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=ACP+unveils+tools+to+improve+health+outcomes+in+patients+following+ACS+event#news1259">
<title>ACP unveils tools to improve health outcomes in patients following ACS event</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=ACP+unveils+tools+to+improve+health+outcomes+in+patients+following+ACS+event#news1259</link>
<dc:date>2013-04-18</dc:date>
<description><![CDATA[Interventions aim to improve health outcomes in patients after blood flow to heart muscle is suddenly blocked.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Steriod+use+doubles+risk+of+venous+thromboembolism#news1258">
<title>Steriod use doubles risk of venous thromboembolism</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Steriod+use+doubles+risk+of+venous+thromboembolism#news1258</link>
<dc:date>2013-04-16</dc:date>
<description><![CDATA[Glucocorticoids may increase the risk of venous thromboembolism (VTE), irrespective of how they are administered, suggests a large, population-based case–control study from Denmark.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=New+Drugs+Better+Value+Than+Warfarin#news1257">
<title>New Drugs Better Value Than Warfarin</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=New+Drugs+Better+Value+Than+Warfarin#news1257</link>
<dc:date>2013-04-18</dc:date>
<description><![CDATA[The three newest anticoagulants -- dabigatran […], apixaban […], and rivaroxaban […] -- are cost-effective relative to warfarin for preventing stroke in patients with nonvalvular atrial fibrillation, researchers found.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Stent+type+may+influence+thrombosis+rates+in+patients+with+diabetes#news1256">
<title>Stent type may influence thrombosis rates in patients with diabetes</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Stent+type+may+influence+thrombosis+rates+in+patients+with+diabetes#news1256</link>
<dc:date>2013-04-16</dc:date>
<description><![CDATA[Everolimus-eluting stents are associated with lower rates of stent thrombosis compared with paclitaxel-eluting stents in those with diabetes, but after adjustment, the composite rate of target lesion revascularization major adverse events was similar between stent types at 1 year, study results have concluded.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Women+experiencing+still+birth+are+more+likely+to+develop+blood+clots%2C+says+study#news1255">
<title>Women experiencing still birth are more likely to develop blood clots, says study</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Women+experiencing+still+birth+are+more+likely+to+develop+blood+clots%2C+says+study#news1255</link>
<dc:date>2013-04-16</dc:date>
<description><![CDATA[Women who have suffered a still birth or have medical conditions including varicose veins, inflammatory bowel disease (IBD) or heart disease are at greater risk of developing dangerous blood clots after giving birth, a study has revealed.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=European+committee+adopts+positive+opinion+on+rivaroxaban+for+ACS#news1254">
<title>European committee adopts positive opinion on rivaroxaban for ACS</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=European+committee+adopts+positive+opinion+on+rivaroxaban+for+ACS#news1254</link>
<dc:date>2013-04-16</dc:date>
<description><![CDATA[The Committee for Medicinal Products for Human Use has adopted a positive opinion for expanding the indication of rivaroxaban to include patients with ACS, according to a press release issued by the agency.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Thrombosis+publications+recommended+by+the+Board+of+Advisers+has+been+updated+for+February+2013.#news1253">
<title>Thrombosis publications recommended by the Board of Advisers has been updated for February 2013.</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Thrombosis+publications+recommended+by+the+Board+of+Advisers+has+been+updated+for+February+2013.#news1253</link>
<dc:date>2013-03-21</dc:date>
<description><![CDATA[New Thrombosis publications available for February 2013.]]></description>
</item>
<item rdf:about="http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Pregnancy-associated+plasma+protein+A+predicts+cardiovascular+events%3A+Study#news1252">
<title>Pregnancy-associated plasma protein A predicts cardiovascular events: Study</title>
<link>http://www.thrombosisadviser.com/scripts/pages/en/resources/newsticker/index.php?WT.cusRSSfeedLink=Pregnancy-associated+plasma+protein+A+predicts+cardiovascular+events%3A+Study#news1252</link>
<dc:date>2013-03-20</dc:date>
<description><![CDATA[Higher levels of pregnancy-associated plasma protein A (PAPP-A) were associated with an increased risk of cardiovascular events in people with cardiac chest pain that developed as a result of heart disease/coronary artery disease, according to a study published in CMAJ.]]></description>
</item>
</rdf:RDF>